Featured Products
more+
-
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)-CAS:1360105-53-8Molecular Formula:
-
S-ETHYLISOTHIOUREA HYDROBROMIDECAS:1071-37-0Molecular Formula:
-
6-chloro-2-methyl-2H-indazol-5-amineCAS:1893125-36-4Molecular Formula:
-
DimethylthioformamideCAS:758-16-7Molecular Formula:C3H7NS
-
Dicobalt octacarbonylCAS:10210-68-1Molecular Formula:Co2(CO)8
-
2,3,4-TrihydroxybenzaldehydeCAS:2144-08-3Molecular Formula:C7H6O4
-
DL-Serinohydrazide monohydrochlorideCAS:55819-71-1Molecular Formula:C3H9N3O2.ClH
-
2,4,6-Tri(2,4-dihydroxyphenyl)-1,3,5-triazineCAS:2125-23-7Molecular Formula:C21H15N3O6
New Arrivals
more+
-
(R)-1-(tert-Butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acidCAS:364077-84-9Molecular Formula:C10H15NO5
-
Guanidine hydrochlorideCAS:50-01-1Molecular Formula:CH5N3HCl
-
Dimethyl glutarateCAS:1119-40-0Molecular Formula:C7H12O4
-
Propylphosphonic anhydrideCAS:68957-94-8Molecular Formula:C9H21O6P3
-
1,1'-Thiocarbonyldi-2,2'-pyridoneCAS:102368-13-8Molecular Formula:C11H8N2O2S
-
2-Chloro-4-methylpyrimidineCAS:13036-57-2Molecular Formula:C5H5ClN2
-
HalquinolCAS:8067-69-4Molecular Formula:C18H11Cl3N2O2
-
Polyadenylic acid potassium saltCAS:26763-19-9Molecular Formula:C10H13KN5O7P

Contact us
Email::[email protected]
News
more+
-
11-26Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye DiseaseAllegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-cont
-
11-15Janssen Licenses "Flexible Antibody" Technology from F-star in New CollabClinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the Eu
-
11-09Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual MeetingWALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E
Technical FAQ
more+
Services
Notice